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 ABSTRACT 
Introduction: Early prediction of massive transfusion (MT) is critical in the management 
of severely injured trauma patients. Variables available early after injury including 
physiologic, laboratory and rotation thromboelastometric (ROTEM
®
) parameters were 
evaluated as predictors for the need of MT. 
Methods: After IRB approval, we retrospectively reviewed a cohort of severely injured 
trauma patients (ISS ≥ 16) admitted to a level 1 trauma center with available ROTEM® 
measurements on hospital admission during a 1-year study period. Patients with isolated 
head injury [Abbreviated Injury Scale (AIS) head ≥3 and AIS chest, abdomen, and 
extremity <3] and patients with a penetrating mechanism of injury were excluded. 
Patients who received a MT (≥ 10 units PRBC within 24 hours of admission) were 
compared with patients who did not. Variables independently associated with MT were 
identified using stepwise logistic regression. 
Results: A total of 53 patients met inclusion criteria. Of these, 18 patients (34.0%) 
received a MT and 35 patients (66.0%) did not. Massively transfused patients had 
significantly lower baseline hemoglobin values (7.9 ± 0.4 vs. 11.4 ± 0.4 g/dL; p<0.001) 
and a trend towards higher lactate (4.8 ± 0.8 vs. 3.0 ± 0.3 mmol/L; p=0.056) and base 
deficit values (5.9 ± 1.1 vs. 3.6 ± 0.6 mmol/L; p=0.052). Mean INR (1.46 ± 0.07 vs. 1.22 
± 0.05; p=0.001) and partial thromboplastin times (42.4 ± 5.0 vs. 29.7 ± 1.8 sec; p<0.001) 
were significantly higher in MT patients. Patients receiving a MT had significantly 
altered ROTEM
®
 values on admission compared to non-MT patients. An increase in the 
clot formation time (471.3 ± 169.9 vs. 178.1 ± 19.9 sec; p=0.001), a shortening of the 
*Abstract
 maximum clot firmness (37.5 ± 2.9 vs. 50.7 ± 1.4 mm; p<0.001), and a shortening of the 
clot amplitude at all time-points (10/20/30 minutes) were observed in massively 
transfused trauma patients. Variables independently associated with MT included a 
hemoglobin level ≤ 10 g/dL and an abnormal maximum clot firmness value [area under 
the ROC curve: 0.831 (95% CI: 0.719 – 0.942; p<0.001)].  
Conclusion: Hemoglobin ≤ 10 g/dL and an abnormal maximum cloth firmness 
measured by rotation thromboelastometry on admission reliably predict the need for 
massive transfusion. Prospective validation of the effectiveness of thromboelastometry to 
guide the transfusion practice following trauma is warranted. 
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INTRODUCTION 
 MassiveTraumatic hemorrhage following injury results in coagulopathy, which 
subsequently leads to further blood loss. Several mechanisms including tissue injury, 
hemodilution, hypothermia, acidosis, and inflammation are postulated to be the main 
causes ofpredispose for traumatic coagulopathy.
1-3
  A recent report by Brohi and 
colleagues
4
, however, suggested an alternative coagulopathy pathway following major 
trauma independent of clotting-factor deficiency. Early traumatic coagulopathy occurred 
exclusively in the setting of tissue hypoperfusion resulting in activation of the 
thrombomodulin-protein C system, higher tPA levels, and fibrinolysis.  While further 
investigations to fully comprehend pathways of acute coagulopathy are warranted, 
coagulation abnormalities have been demonstrated to be associated with poor outcomes.
1, 
5, 6
 Additionally, it has been observed that coagulopathy occurring in the early 
posttraumatic phase correlates closely with massive transfusion (MT) requirement.
1, 5, 7
 
After increasing number of studies demonstrating improved outcomes pertinent due to 
agressive plasma and platelet replacements in patients requiring MT
8-10
, many trauma 
centers have instituted massive transfusion protocols.
11-15
  Most MT protocols, however, 
are triggered by physicianss only after when clinical suspicion of a significantlarge blood 
loss is imminent, or  when transfusion of massive amounts of packed red cells has already 
been established.   
Therefore, Sseveral scoring systems have recently been proposed to predict the need for 
MT.
16-21
 However, the vast majority of suchggested algorithms require time-consuming 
laboratory work-up, injury severity calculations, or mathematical computations. 
Relatively scantlittle is the documentationed pertinent to about point-of-care devices, 
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such as thromboelastogaphy (TEG
®
) and rotation thromboelastometry (ROTEM
®
), as 
predictors of transfusion requirement after injury.
22-24
  TEG
®
 and ROTEM
®
 may 
overcome several limitations of routine coagulation tests and may further provide useful 
information on platelet function.
25-27
 Subsequent transfusion algorithms based on point-
of-care assays have been promising resulting in reduced transfusion requirements in 
cardiac
28, 29
 and hepatic
30, 31
 surgery.  
The purpose of the present study was to determine the role of ROTEM
®
 as the 
predictor of MT following trauma. In addition to the ROTEM
®
 values, physiologic and 
laboratory variables readily available early after injury were also evaluated as predictors 
of MT. 
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METHODS 
After approval by the Institutional Review Board, we retrospectively reviewed a 
cohort of severely injured trauma patients admitted to the Division of Trauma Surgery of 
the University Hospital of Zurich, a referral trauma center, from January through 
December 2006. The inclusion criteria were an Injury Severity Score (ISS) > 16 and 
available ROTEM
®
 measurements on hospital admission. Patients with isolated head 
injury [Abbreviated Injury Scale (AIS) head ≥3 and AIS chest, abdomen, and extremity 
<3] (n=48) and patients with a penetrating mechanism of injury (n=19) were excluded. A 
MT was defined as a transfusion of 10 or more packed red blood cell (PRBC) units 
during the initial 24 hours after admission. 
Demographic and clinical information collected included age, gender, blood 
pressure on admission, Glasgow Coma Scale (GCS) score on admission, ISS, and AIS for 
each body region (head, chest, abdomen, extremity). Continuous variables were 
converted into dichotomous variables using clinically relevant cut-points (age ≥ 55 years, 
systolic blood pressure < 90 mmHg, GCS ≤ 8, ISS ≥ 25, AIS ≥ 3). All hemoglobin 
values, base deficit, lactate, pH values, platelet counts, international normalized ratio 
(INR) values, and partial thromboplastin times (PTT) obtained on admission were also 
accrued. The number of PRBC, fresh frozen plasma (FFP), and platelet units transfused 
were abstracted. 
 
Point-of-care Devices 
TEG
®
 and ROTEM
®
 provide a real-time graphic assessment of clot formation and 
subsequent lysis. Blood is incubated at 37˚C in a heated cup. Within this cup is 
  5 
suspended a pin connected to a detector system. This is a torsion wire in case of TEG
®
 
and an optical detector in ROTEM
®
. The cup and pin are oscillated relative to each other. 
The movement is initiated from either the cup (TEG
®
) or the pin (ROTEM
®
). As fibrin 
forms between the cup and pin the transmitted rotation from the cup to pin (TEG
®
) or 
impedance of the rotation of the pin (ROTEM
®
) is detected at the pin and a trace is 
generated.
25
 
During the study period, rotation thromboelastometry measurements were 
obtained at the discretion of the attending physician in severely injured patients. Blood 
samples were drawn and analyzed in a ROTEM
®
 analyzer Pentapharm GmbH (Munich, 
Germany) within 15 minutes of admission. The ROTEM® coagulation analyzer and the 
parameters of thromboelastometry have been described elsewhere.
32
  Briefly, ROTEM
®
 
measurements graphically display the changes in viscoelasticity at all stages of the 
developing and resolving clot. In the ROTEM
®
 analyzer, coagulation is mildly activated 
either with ellagic acid (INTEM test) or tissue factor from rabbit brain (EXTEM test). 
Both, the INTEM as well as the EXTEM test were performed in the study cohort. The 
test time for ROTEM
®
 is typically 15 to 20 minutes. ROTEM
®
 parameters analyzed in 
this study included the time until initial fibrin formation [clotting time (CT)], the kinetics 
of fibrin formation and clot development [clot formation time (CFT) and the alpha angle], 
the stability of the fibrin clot at various time-points [amplitude of the clot at 10 minutes 
(A10), at 20 minutes (A20), and at 30 minutes (A30)] and the ultimate strength and 
stability of the fibrin clot [maximum clot firmness (MCF)]. The reference ranges utilized 
for ROTEM
®
 parameters were previously described by Lang and colleagues.
32
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STATISTICAL ANALYSIS 
The demographic and clinical characteristics between massively and non-massively 
transfused trauma patients were evaluated using bivariate analysis. Laboratory parameters 
including coagulation markers, base deficit, lactate and ROTEM
®
 parameters were also 
compared between the two cohorts. The p values for categorical variables were derived 
from the Chi-square test or 2-sided Fisher’s exact test and for continuous variables the 
Mann-Whitney test was deployed.  
To identify risk factors independently associated with the need for a MT, a stepwise 
logistic regression was utilized and risk factors from the bivariate analysis with a p value 
<0.2 were included in the model. The area under the receiver operator characteristic 
(ROC) curve was constructed to evaluate the model’s discriminating power to predict 
MT. 
Values are reported as mean ± standard error of the mean (SEM) for continuous 
variables and as percentages for categorical variables. All analyses were performed using 
the Statistical Package for Social Sciences version 12.0 (SPSS Inc., Chicago, IL). 
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RESULTS 
During the 1-year study period, 53 patients met inclusion criteria. Of these, 18 
patients (34.0%) received a MT and 35 patients (66.0%) did not. The average age of these 
patients was 39.6 ± 2.5 years and the mean ISS was 31.1 ± 1.7. Detailed demographic 
data, injury characteristics and major surgical procedures of the study groups are depicted 
in Table 1. Severe traumatic brain injury (AIS head ≥ 3) was present in 64.2%. The 
predominant intracranial injuries included intraparenchymal hematoma (28.3%), subdural 
hematoma (24.5%), subarachnoid hemorrhage (20.8%), and epidural hematoma (17.0%). 
Survival to discharge was 61% in the MT group and 66% in the non-MT group 
(p=0.741), respectively.  
Patients in the MT group received on average 22.3 ± 3.9 units PRBC during the 
initial 24 hours of admission compared to 2.7 ± 0.5 units in the non-MT group (p<0.001). 
Likewise, the transfusion rates of FFP (16.4 ± 3.0 vs. 1.9 ± 0.5 units; p<0.001) and 
platelets (14.3 ± 3.0 vs. 0.8 ± 0.4 units; p<0.001) were significantly higher in the MT 
group compared to their non-MT counterparts. A detailed description of the blood 
components utilized for resuscitationtransfused within different time frames of the initial 
24 hours is provided in Table 2. 
Table 3 depicts admission laboratory values comparing the MT and non-MT 
groupcohorts. Massively transfused patients experienced significantly lower baseline 
hemoglobin values and an obvious strong trend towards higher lactate and base deficit 
values. Mean INR and partial thromboplastin times were significantly higher in the MT 
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patients. Additionally, a trend towards lower platelet counts in the MT group was 
observed.  
Patients receiving a MT had significantly different values in almost all ROTEM
®
 
tests on admission compared to non-MT patients (Table 4). A significant increase in the 
CFT, a shortening of the MCF and a shortening of the clot amplitude at all time-points 
(A10, A20, A30) were observed in massively transfused trauma patients (Table 4).  
Bivariate analysis was performed to identify risk factors associated with the need 
for MT (Figure 1). The results of the stepwise logistic regression analysis are presented in 
Table 5. Variables independently associated with the need for MT included a hemoglobin 
level ≤ 10 g/dL and an abnormal INTEM MCF value. Using these two factors as a 
predictive model, the area under the ROC curve was 0.831 (95% CI: 0.719 – 0.942; 
p<0.001). Using the INTEM MCF as a single variable to predict MT revealed an area 
under the ROC curve of 0.824 (95% CI: 0.708 - 0.941; p<0.001).  
  9 
DISCUSSION 
Point-of-care devices have been utilizedsed for many years  to guide effective 
blood component and drug administration during major surgery. Numerous studies, the 
majority of those performed in patients undergoing liver
30, 31
 or cardiac
28, 29
 surgery, 
noted reported a reduction in transfusion requirement and subsequent mortality when 
transfusion therapy was based on TEG
®
/ROTEM
®
 results as compared to therapy guided 
by conventional coagulation markers. Recently, in a before-after study, Johansson et al.
33
 
reported the effect a reduction ofon mortality usingof point-of-care guided transfusion 
therapy in massively bleeding patients, 21% of those being trauma patients. In this 
examination, Ppatients treated according to the TEG
®
 results had a significantly lower 
30-day mortality as compared to controls (20% vs. 32%). 
While the beneficial value of point-of-care devices to tailor blood component 
requirements therapyduring transfusion therapy has been previously shown, the goal of 
the present study was to examine the role of ROTEM
®
 in the very early prediction of MT 
in trauma patientsfollowing trauma. One of the earliest attempts to evaluate the 
usefulness of point-of-care assays in the assessment of the coagulation status in trauma 
victims was performed conducted by Kaufmann et al. in 1997.
22
 In their study, including 
69 blunt trauma patients, 65% demonstrated hypercoagulability upon hospital arrival 
whereas only 10% were hypocoagulable. Of the hypocoagulable patients, 86% received 
blood products within the first 24 hours, whereas only 4% of the hypercoagulable 
patients, and none of the patients with completely normal TEG
®
 parameters required 
transfusion within the first 24 hours. A hypocoagulable TEG
®
 was associated with 
increased ISS and only ISS and TEG
®
 were predictive of transfusion requirements within 
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the first 24 hours. NeverthelessHowever, the vast majority of patients in that study did 
not receive a MT. In patients sustaining penetrating insults, Plotkin et al. 
23
 demonstrated 
that the maximum clot amplitude significantly correlated with the total amount of blood 
products used within the initial 24 hours. Conventional coagulation variables, such as 
INR, prothrombin time and partial thromboplastin time, discriminated hypo- from normo-
/hypercoagulopathic patients, but did not predict transfusion requirements. Likewise, in 
Martini’s swine model34, TEG® appeared to be better superior in detecting mechanisms 
associated with coagulopathy induced by hypothermia and hemorrhage than conventional 
coagulation markers.  
In the present examination, we evaluated several physiologic, laboratory as well 
as ROTEM
®
 variables and their ability to predict the need for MT.  ROTEM
®
 parameters 
on admission and, in particular the INTEM channel, discriminated significantly the 
massively transfused from the non-massively transfused blunt trauma patients. 
Additionally, the maximum cloth firmness (INTEM MCF) in combination with a low 
hemoglobin value (≤ 10 g/dL) was proved to be independently associated with the need 
for MT (area under the ROC curve: 0.824) and is in this regard comparable to 
thoseagreement with models already published in the literature.
7, 16-20
 Both variables are 
promptly available in the resuscitation bay. The hemoglobin values can be measured in a 
point-of-care device within minutes. Likewise, ROTEM
®
 can be conducted rapidly in the 
emergency department with readily available results providing a wide range of 
information data on the patient’s coagulation status.35  
Although this is one of the first studies examining the role of ROTEM
®
 in the 
prediction of MT, there are several limitations, the most important being the retrospective 
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nature of the data analysis. Evaluation of the coagulation status was performed in 
severely injured patients at the discretion of the attending physician, and may therefore 
have resulted in a selection bias. Data on fibrinolysis, guiding transfusion practice in both 
ROTEM
36
 and TEG studies
24
, was not available for the current analysis. Lastly, our study 
conclusions are limited by the small sample size and the wide variety of injury patterns 
included. Almost two thirds of our study cohort suffered severe head injuries, a patient 
population  in particularly prone  to be at high risk for developing coagulopathy, 
however, pathways of coagulation abnormalities in head injured patients are likely to be 
very different to those of suffering torso trauma.
37-39
  
 
CONCLUSION 
Hemoglobin ≤ 10 g/dL and an abnormal maximum cloth firmness measured by 
rotation thromboelastometry on admission reliably predict the need for massive 
transfusion. Further pProspective studies to validatevalidation of the effectiveness of 
thromboelastometry to guide the transfusion management practice in trauma 
patientsfollowing trauma isare warranted. 
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 Table 1. Demographic and Clinical Injury Characteristics Comparing the Massive and Non-Massive Transfusion Group 
 
  
All Patients 
(n=53) 
MT 
(n=18) 
Non-MT 
(n=35) 
p Value 
Age (years), mean ± SEM 39.6 ± 2.5 42.1 ± 4.2 38.3 ± 3.1 0.447 
Age ≥ 55 years 22.6% (12/53) 27.8% (5/18) 20.0% (7/35) 0.730 
Male 75.5% (40/53) 61.1% (11/18) 82.9% (29/35) 0.101 
GCS ≤ 8 78.8% (41/52) 76.5% (13/17) 80.0% (28/35) 1.000 
SBP < 90 mmHg 19.2% (10/52) 35.3% (6/17) 11.4% (4/35) 0.062 
Heart rate > 110/min 15.4% (8/52) 17.6% (3/17) 14.3% (5/35) 1.000 
ISS, mean ± SEM 31.1 ± 1.7 37.1 ± 3.2 28.0 ± 1.8 0.012 
ISS ≥ 25 66.0% (35/53) 77.8% (14/18) 60.0% (21/35) 0.196 
Head AIS ≥ 3 64.2% (34/53) 50.0% (9/18) 71.4% (25/35) 0.123 
Chest AIS ≥ 3 62.3% (33/53) 66.7% (12/18) 60.0% (21/35) 0.635 
Abdomen AIS ≥ 3 43.4% (23/53) 77.8% (14/18) 25.7% (9/35) <0.001 
Extremity AIS ≥ 3 26.4% (14/53) 44.4% (8/18) 17.1% (6/35) 0.049 
Surgical Procedures on Admission     
Craniotomy / Craniectomy 24.5% (13/53) 22.2% (4/18) 25.7% (9/35) 1.000 
Thoracotomy / Sternotomy 11.3% (6/53) 27.8% (5/18) 2.9% (1/35) 0.014 
Laparotomy 15.1% (8/53) 38.9% (7/18) 2.9% (1/35) 0.001 
Pelvic Clamp / External Fixator 9.4% (5/53) 27.8% (5/18) 0% (0/35) 0.003 
External Fixator Extremity 11.3% (6/53) 22.2% (4/18) 5.7% (2/35) 0.164 
 
Abbreviations: MT, Massive Transfusion; GCS, Glasgow Coma Scale; SBP, systolic blood pressure; ISS, Injury Severity Score; SEM, 
standard error of the mean; AIS, Abbreviated Injury Scale. 
 
Tables
 Table 2. Blood Component Summary for Different Time Frames within the First 24 Hours  
 
 
Total 
(n=53) 
MT 
(n=18) 
Non-MT 
(n=35) 
p Value 
PRBC (Units)     
   0 – 6 hrs 6.9 ± 1.5 17.1 ± 3.2 1.7 ± 0.4 <0.001 
   6 – 12 hrs 1.4 ± 0.4 3.1 ± 1.0 0.5 ± 0.2 0.002 
   12 – 24 hrs 1.1 ± 0.3 2.1 ± 0.9 0.6 ± 0.3 0.064 
FFP (Units)     
   0 – 6 hrs 5.0 ± 1.0 12.1 ± 2.2 1.3 ± 0.3 <0.001 
   6 – 12 hrs 1.0 ± 0.3 2.4 ± 0.9 0.2 ± 0.1 0.005 
   12 – 24 hrs 0.9 ± 0.3 1.9 ± 0.8 0.4 ± 0.2 0.043 
PLT (Units)     
   0 – 6 hrs 3.2 ± 0.9 9.0 ± 2.1 0.3 ± 0.2 <0.001 
   6 – 12 hrs 1.1 ± 0.5 2.8 ± 1.3 0.2 ± 0.2 0.007 
   12 – 24 hrs 1.1 ± 0.4 2.4 ± 1.0 0.3 ± 0.2 0.009 
FFP:PRBC ratio at 24 hrs 0.49 ± 0.08 0.76 ± 0.07 0.35 ± 0.11 <0.001 
PLT:PRBC ratio at 24 hrs 0.28 ± 0.06 0.63 ± 0.11 0.10 ± 0.05 <0.001 
 
Values are expressed as Mean ± SEM 
 
Abbreviations: MT, Massive Transfusion; PRBC, Packed Red Blood Cells; FFP, Fresh Frozen Plasma; PLT, Platelets; SEM, Standard 
Error of the Mean
 Table 3. Admission Laboratory Values Comparing the Massive and Non-Massive Transfusion Group  
 
  
All Patients 
(n=53) 
MT 
(n=18) 
Non-MT 
(n=35) 
p Value 
Hemoglobin (g/dL) 10.2 ± 0.4 7.9 ± 0.4 11.4 ± 0.4 <0.001 
Hematocrit (%) 31.5 ± 1.2 24.2 ± 1.3 35.1 ± 1.2 <0.001 
Lactate (mmol/L) 3.6 ± 0.4 4.8 ± 0.8 3.0 ± 0.3 0.056 
Base Deficit (mmol/L) 4.4 ± 0.6 5.9 ± 1.1 3.6 ± 0.6 0.052 
pH 7.29 ± 0.02 7.24 ± 0.04 7.31 ± 0.01 0.301 
INR 1.30 ± 0.04 1.46 ± 0.07 1.22 ± 0.05 0.001 
PTT (sec) 34.1 ± 2.2 42.4 ± 5.0 29.7 ± 1.8 <0.001 
PLT (x10
3
) 170.0 ± 8.4 147.9 ± 17.4 181.4 ± 8.7 0.074 
 
Values are expressed as Mean ± SEM 
 
Abbreviations: MT, Massive Transfusion; SEM, Standard Error of the Mean; INR, International Normalized Ratio; PTT, Prothrombin 
Time; PLT, Platelets 
 Table 4. Rotation Thromboelastography Parameters in the Massive and Non-Massive Transfusion Group 
 
  
Normal 
Ranges
32
 
All Patients 
(n=53) 
MT 
(n=18) 
Non-MT 
(n=35) 
p Value 
EXTEM      
CT (sec)  38-79 115.8 ± 11.1 107.9 ± 10.1 120.0 ± 16.2 0.583 
CFT (sec) 34-159 284.0 ± 52.0 434.2 ± 136.7 201.7 ± 21.5 0.009 
 angle  63-83 54.2 ± 2.0 49.8 ± 2.5 56.6 ± 2.6 0.044 
A10 (mm) 43-65 34.7 ± 1.9 29.9 ± 2.4 37.2 ± 2.5 0.032 
A20 (mm) 50-71 41.3 ± 2.1 36.9 ± 3.0 43.6 ± 2.7 0.054 
A30 (mm) 50-69 43.8 ± 2.1 38.6 ± 3.6 46.3 ± 2.4 0.051 
MCF (mm) 50-72 43.4 ± 2.0 39.3 ± 2.7 45.5 ± 2.6 0.041 
INTEM      
CT (sec) 100-240 239.7 ± 32.7 232.2 ± 19.2 243.3 ± 48.0 0.050 
CFT (sec) 30-110 267.9 ± 56.1 471.3 ± 169.9 178.1 ± 19.9 0.001 
 angle 70-83 57.4 ± 1.9 48.5 ± 3.2 61.9 ± 2.0 0.001 
A10 (mm) 44-66 36.8 ± 1.6 28.6 ± 2.4 40.9 ± 1.7 <0.001 
A20 (mm) 50-71 44.3 ± 1.7 35.7 ± 3.3 48.3 ± 1.6 0.001 
A30 (mm) 57-72 46.9 ± 1.5 39.8 ± 2.7 50.0 ± 1.5 0.002 
MCF (mm) 50-72 46.3 ± 1.6 37.5 ± 2.9 50.7 ± 1.4 <0.001 
 
Values are expressed as Mean ± SEM 
 
Abbreviations: MT, Massive Transfusion; CT, Clotting Time; CFT, Clot Formation Time; A10/20/30, Clot Firmness 10/20/30 
Minutes after CT; MCF, Maximum Clot Firmness 
 
 Table 5. Independent Risk Factors for Massive Transfusion in Severely Injured Trauma Patients 
 
Step Variable Adjusted Odds Ratio (95% CI) Adjusted p Value R
2
 
1 Hemoglobin ≤ 10 g/dL 18.18 (2.73 - 125.00) 0.003 0.350 
2 Abnormal INTEM MCF 8.47 (1.19 - 62.50) 0.033 0.135 
Risk factors entered into the model (p<0.2): Systolic blood pressure < 90 mmHg vs. ≥ 90 mmHg; hemoglobin ≤ 10 g/dL vs. > 10 
g/dL; Base Deficit ≤ 6 mmol/L vs. > 6 mmol/L; INR > 1.2 vs. ≤ 1.2; PTT > 36 sec vs. ≤ 36 sec; Platelet count < 100 vs. ≥ 100; 
Abnormal vs. Normal EXTEM: CFT, alpha angel, A10, A20, A30, MCF; Abnormal vs. Normal INTEM: alpha angel, A10, A20, A30, 
MCF 
 
Abbreviations: CI, Confidence Interval; MCF, Maximum Clot Firmness; INR, International Normalized Ratio; PTT, Partial 
Thromboplastin Time; CFT, Clot Formation Time; A10/20, Clot Firmness x Minutes after CT 
 
 
 Figure 1. Risk for Massive Transfusion by Risk Factors (p<0.2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: SBP, Systolic Blood Pressure; Hb, Hemoglobin; BD, Base Deficit; INR, International Normalized Ratio; aPTT, 
Activated Partial Thromoplastin Time; PLT, Platelets; CFT, Clot Formation Time; A10/20, Clot Amplitude at 10/20 Minutes; MCF, 
Maximum Clot Firmness 
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